As Covid Drug Cash Dwindles, Vigonvita Targets New Remedies

Quick Summary:

A Chinese biotech that made a name for itself by co-developing an anti-Covid drug has filed for a stock market listing to fund research into tackling other conditions

Key Takeaways: Vigonvita works closely with the Chinese Academy of Sciences through its founder and biggest shareholder, research scientist Shen Jingshan

After selling rights to its flagship anti-viral product, the drug developer fell back into the red last year As Chinese biotechs beat a path to Hong Kong's IPO market, hoping to catch the eye of investors, one drug developer can point to a commercially launched Covid treatment as proof of its capability.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: The Bamboo Works

Category: InvestingBusiness

Markets: United StatesChinaHong KongUzbekistan

Topics: Biotech Asia IPOs Contributors Benzinga

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-02-21 @ 10:26:14 (1 days ago)

News Timezone: GMT +8:00

News Source URL: benzinga.com

Language: English

Article Length: 840 words

Reading Time: 5 minutes read

Sentences: 35 lines

Sentence Length: 24 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Benzinga

News ID: 26316482

View Article Analysis

About Benzinga

Main Topics: InvestingBusiness

Official Website: benzinga.com

Year Established: 2010

Headquarters: United States

News Last Updated: 2 days ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #54

Publisher Details

Frequently Asked Questions